Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Lipid-based nanoformulations for peptide delivery
Inserm, France.
RISE., SP – Sveriges Tekniska Forskningsinstitut, SP Kemi Material och Ytor, Life Science.ORCID-id: 0000-0003-4742-1702
Inserm, France.
Inserm, France.
Vise andre og tillknytning
2016 (engelsk)Inngår i: International Journal of Pharmaceutics, ISSN 0378-5173, E-ISSN 1873-3476, Vol. 502, nr 1-2, s. 80-97Artikkel, forskningsoversikt (Fagfellevurdert) Published
Resurstyp
Text
Abstract [en]

Nanoformulations have attracted a lot of attention because of their size-dependent properties. Among the array of nanoformulations, lipid nanoformulations (LNFs) have evoked increasing interest because of the advantages of their high degree of biocompatibility and versatility. The performance of lipid nanoformulations is greatly influenced by their composition and structure. Therapeutic peptides represent a growing share of the pharmaceutical market. However, the main challenge for their development into commercial products is their inherent physicochemical and biological instability. Important peptides such as insulin, calcitonin and cyclosporin A have been incorporated into LNFs. The association or encapsulation of peptides within lipid-based carriers has shown to protect the labile molecules against enzymatic degradation. This review describes strategies used for the formulation of peptides and some methods used for the assessment of association efficiency. The advantages and drawbacks of such carriers are also described.

sted, utgiver, år, opplag, sider
Elsevier, 2016. Vol. 502, nr 1-2, s. 80-97
Emneord [en]
Drug delivery, Lipids, Nanoformulations, Peptides
HSV kategori
Identifikatorer
URN: urn:nbn:se:ri:diva-90DOI: 10.1016/j.ijpharm.2016.02.019Scopus ID: 2-s2.0-84959179307OAI: oai:DiVA.org:ri-90DiVA, id: diva2:930616
Tilgjengelig fra: 2016-05-24 Laget: 2016-04-28 Sist oppdatert: 2019-06-17bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Personposter BETA

Boge, LukasBysell, Helena

Søk i DiVA

Av forfatter/redaktør
Boge, LukasBysell, Helena
Av organisasjonen
I samme tidsskrift
International Journal of Pharmaceutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 18 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
v. 2.35.7